Drugs / GENA-104A16
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06235541 | Feb 2024 → Sep 2026 | cancer | Genome & Company | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GENA-104A16 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06235541 ↗ |
| Modality | Monoclonal antibody | “Anti-contactin4 [CNTN4] Monoclonal Antibody [mAb]” NCT06235541 ↗ |
| Route | Intravenous | “as intravenous (IV) infusion” NCT06235541 ↗ |
| Target | CNTN4 | “Anti-contactin4 [CNTN4]” NCT06235541 ↗ |